Fresh off its $89.7 million jury award in a patent infringement case against GlaxoSmithKline (NYSE:GSK), British inhaler company Vectura has petitioned the court for an additional $44 million.
On May 16, a jury in U.S. District Court for the District of Delaware awarded Vectura damages for the period from August 2016 through December 2018 for an infringement on Vectura’s U.S. patent 8303991 by sales of three of GlaxoSmithKline’s Ellipta products.
The jury based its award on royalties GSK earned from the infringed patent based on U.S. sales of the accused products from August 1, 2016 through December 31, 2018, according to Vectura’s recent filing for additional damages.
Get the full story on our sister site, Drug Delivery Business.